{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:26:32Z","timestamp":1764174392561,"version":"3.41.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.schres.2017.06.020","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T19:01:08Z","timestamp":1497898868000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-4060","authenticated-orcid":false,"given":"Chih-Wei","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5320-1151","authenticated-orcid":false,"given":"Liang-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2017.06.020_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-0500-1-25","article-title":"Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference?","volume":"1","author":"Bakare","year":"2008","journal-title":"BMC. Res. Notes"},{"issue":"7","key":"10.1016\/j.schres.2017.06.020_bb0010","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.euroneuro.2015.03.008","article-title":"Regulatory and clinical aspects of psychotropic medicinal products bioequivalence","volume":"25","author":"Balkowiec-Iskra","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.06.020_bb0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/sj.clpt.6100358","article-title":"Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects","volume":"82","author":"Bertilsson","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.schres.2017.06.020_bb0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2146\/ajhp080595","article-title":"Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data","volume":"67","author":"Bobo","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"10","key":"10.1016\/j.schres.2017.06.020_bb0025","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.clinthera.2010.09.013","article-title":"Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: a single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand","volume":"32","author":"Boonleang","year":"2010","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0030","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","article-title":"The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs","volume":"25","author":"Borgheini","year":"2003","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.schres.2017.06.020_bb0035","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pharep.2015.08.017","article-title":"Therapeutic equivalence of antipsychotics and antidepressants - a systematic review","volume":"68","author":"Cessak","year":"2016","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.schres.2017.06.020_bb0040","first-page":"222","article-title":"Comparative pharmacokinetics of two sulpiride formulations in healthy volunteers","volume":"5","author":"Chen","year":"1989","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"3","key":"10.1016\/j.schres.2017.06.020_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010802","article-title":"Impact of universal health coverage on urban-rural inequity in psychiatric service utilisation for patients with first admission for psychosis: a 10-year nationwide population-based study in Taiwan","volume":"6","author":"Chiang","year":"2016","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.schres.2017.06.020_bb0050","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-015-0269-4","article-title":"The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics","volume":"29","author":"De Hert","year":"2015","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0055","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2710.2006.00784.x","article-title":"Treatment of psychosis: 30 years of progress","volume":"31","author":"De Oliveira","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0060","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","article-title":"Switching from brand-name to generic psychotropic medications: a literature review","volume":"17","author":"Desmarais","year":"2011","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0065","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.schres.2017.06.020_bb0070","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.clinthera.2009.03.008","article-title":"A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions","volume":"31","author":"Elshafeey","year":"2009","journal-title":"Clin. Ther."},{"issue":"20","key":"10.1016\/j.schres.2017.06.020_bb0075","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMp078193","article-title":"The ongoing regulation of generic drugs","volume":"357","author":"Frank","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.schres.2017.06.020_bb0080","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000","volume":"65","author":"Ganguly","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.06.020_bb0085","first-page":"293","article-title":"Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder","volume":"10","author":"Gyorgy","year":"2008","journal-title":"Neuropsychopharmacol. Hung."},{"issue":"11","key":"10.1016\/j.schres.2017.06.020_bb0090","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-142-11-200506070-00006","article-title":"Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997\u20132000","volume":"142","author":"Haas","year":"2005","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.schres.2017.06.020_bb0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/cap.2010.0013","article-title":"Risperidone: switching from brand name to generic","volume":"20","author":"Hardan","year":"2010","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2017.06.020_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpsychires.2008.06.001","article-title":"Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study","volume":"43","author":"Haro","year":"2009","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.06.020_bb0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","article-title":"Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment","volume":"158","author":"Harvey","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.020_bb0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2014.07.015","article-title":"Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia","volume":"158","author":"Hatta","year":"2014","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.06.020_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10597-005-5981-y","article-title":"Clinical equivalence of generic clozapine","volume":"41","author":"Healy","year":"2005","journal-title":"Community Ment. Health J."},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/FTD.0000000000000211","article-title":"Generic olanzapine substitution in patients with schizophrenia: assessment of serum concentrations and therapeutic response after switching","volume":"37","author":"Italiano","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0125","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5414\/CP201509","article-title":"Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers","volume":"49","author":"Khorana","year":"2011","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.schres.2017.06.020_bb0130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","article-title":"Long-term combination antipsychotic treatment in VA patients with schizophrenia","volume":"84","author":"Kreyenbuhl","year":"2006","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.06.020_bb0135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/schbul\/sbs002","article-title":"Effectiveness of sulpiride in adult patients with schizophrenia","volume":"39","author":"Lai","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.020_bb0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2016.01.046","article-title":"Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)","volume":"172","author":"Landolt","year":"2016","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.06.020_bb0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1071\/HC15094","article-title":"The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand","volume":"7","author":"Lessing","year":"2015","journal-title":"J. Prim. Health Care"},{"issue":"9657","key":"10.1016\/j.schres.2017.06.020_bb0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.schres.2017.06.020_bb0155","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.schres.2017.06.020_bb0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40268-012-0002-4","article-title":"Bioequivalence and pharmacokinetic evaluation of two formulations of risperidone 2mg: an open-label, single-dose, fasting, randomized-sequence, two-way crossover study in healthy male Chinese volunteers","volume":"13","author":"Liu","year":"2013","journal-title":"Drugs R&D"},{"issue":"9","key":"10.1016\/j.schres.2017.06.020_bb0165","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5414\/CPP46489","article-title":"Bioequivalence study of a generic quetiapine in healthy male volunteers","volume":"46","author":"Mahatthanatrakul","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.schres.2017.06.020_bb0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","article-title":"Management of schizophrenia in children and adolescents: focus on pharmacotherapy","volume":"71","author":"Masi","year":"2011","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.schres.2017.06.020_bb0175","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.schres.2017.06.020_bb0180","article-title":"Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan","volume":"9","author":"Multhoff","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0185","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/JCP.0000000000000597","article-title":"Time-to-first discontinuation, adherence and persistence in new users of second-generation antipsychotics","volume":"36","author":"Ndukwe","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.06.020_bb0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0091270009347871","article-title":"Does therapeutic equivalence follow bioequivalence? A randomized trial to assess clinical effects after switching from Clozaril to generic clozapine (gen-clozapine)","volume":"50","author":"Oluboka","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"9690","key":"10.1016\/j.schres.2017.06.020_bb0195","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.schres.2017.06.020_bb0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/CPP45293","article-title":"Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets","volume":"45","author":"van Os","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2017.06.020_bb0205","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1192\/bjp.bp.105.017079","article-title":"Generic clozapine: outcomes after switching formulations","volume":"189","author":"Paton","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2017.06.020_bb0210","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/aje\/154.9.854","article-title":"Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data","volume":"154","author":"Schneeweiss","year":"2001","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.schres.2017.06.020_bb0215","first-page":"260","article-title":"Generic substitution\u2014comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product","volume":"88","author":"Verster","year":"1998","journal-title":"S. Afr. Med. J."},{"author":"WHO","key":"10.1016\/j.schres.2017.06.020_bb0220"},{"issue":"6","key":"10.1016\/j.schres.2017.06.020_bb0225","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/JCP.0b013e3182726623","article-title":"Common use of antipsychotic polypharmacy in older Asian patients with schizophrenia (2001\u20132009)","volume":"32","author":"Xiang","year":"2012","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:44:24Z","timestamp":1750362264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417303596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":45,"alternative-id":["S0920996417303596"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.06.020","relation":{},"ISSN":["0920-9964"],"issn-type":[{"type":"print","value":"0920-9964"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}